Li Zhaoming, Song Yue, Zhang Mingzhi, Wei Yiming, Ruan Hang
Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Chin J Cancer Res. 2022 Apr 30;34(2):83-94. doi: 10.21147/j.issn.1000-9604.2022.02.03.
T-cell lymphoblastic lymphoma (T-LBL) is an aggressive neoplasm of precursor T cells, however, detailed genome-wide sequencing of large T-LBL cohorts has not been performed due to its rarity. The purpose of this study was to identify putative driver genes in T-LBL.
To gain insight into the genetic mechanisms of T-LBL development, we performed whole-exome sequencing on 41 paired tumor-normal DNA samples from patients with T-LBL.
We identified 32 putative driver genes using whole-exome sequencing in 41 T-LBL cases, many of which have not previously been described in T-LBL, such as Janus kinase 3 (), Janus kinase 1 (), Runt-related transcription factor 1 () and Wilms' tumor suppressor gene 1 (). When comparing the genetic alterations of T-LBL to T-cell acute lymphoblastic leukemia (T-ALL), we found that JAK-STAT and RAS pathway mutations were predominantly observed in T-LBL (58.5% and 34.1%, respectively), whereas Notch and cell cycle signaling pathways mutations were more prevalent in T-ALL. Notably, besides notch receptor 1 (), mutational status of plant homeodomain (PHD)-like finger protein 6 () was identified as another independent factor for good prognosis. Of utmost interest is that co-existence of and mutation status might provide an alternative for early therapeutic stratification in T-LBL.
Together, our findings will not only provide new insights into the molecular and genetic mechanisms of T-LBL, but also have tangible implications for clinical practice.
T细胞淋巴母细胞淋巴瘤(T-LBL)是一种侵袭性的前体T细胞肿瘤,然而,由于其罕见性,尚未对大量T-LBL队列进行详细的全基因组测序。本研究的目的是鉴定T-LBL中假定的驱动基因。
为深入了解T-LBL发生的遗传机制,我们对41例T-LBL患者的配对肿瘤-正常DNA样本进行了全外显子组测序。
我们通过对41例T-LBL病例进行全外显子组测序鉴定出32个假定的驱动基因,其中许多基因此前在T-LBL中未被描述,如Janus激酶3(JAK3)、Janus激酶1(JAK1)、Runt相关转录因子1(RUNX1)和肾母细胞瘤抑制基因1(WT1)。当比较T-LBL与T细胞急性淋巴细胞白血病(T-ALL)的基因改变时,我们发现JAK-STAT和RAS通路突变在T-LBL中占主导(分别为58.5%和34.1%),而Notch和细胞周期信号通路突变在T-ALL中更普遍。值得注意的是,除了Notch受体1(NOTCH1)外,植物同源结构域(PHD)样指蛋白6(PHF6)的突变状态被确定为另一个良好预后的独立因素。最令人感兴趣的是,NOTCH1和PHF6突变状态的共存可能为T-LBL的早期治疗分层提供一种选择。
总之,我们的发现不仅将为T-LBL的分子和遗传机制提供新的见解,而且对临床实践也有实际意义。